重症成人输血用新鲜红细胞:TRANSFUSE临床试验的经济学评价
TRANSFUSE试验的经济学评价纳入59个ICU、5个国家的成人患者,随机接受最新鲜或最陈旧可用相容红细胞(标准实践)。6个月时EuroQol 5维度3水平效用评分短期储存组0.65 vs 长期储存组0.63(差值0.02,95%CI -0.00至0.04,P=0.10)。短期储存组随访期间再入院天数少3.0天(95%CI -5.3至-0.8,P=0.01),其余资源使用无显著差异。调整后总成本增量-2358美元(95%CI -5586至711),增量质量调整生命年0.003(95%CI -0.003至0.008),均无显著差异。作者认为,不考虑实施最新鲜可用红细胞策略的额外供应成本,该策略与标准输血实践相比未改善生活质量或减少其他成本。
要点
- 在59个ICU、5个国家的成人患者中,最新鲜可用红细胞策略与标准实践相比,6个月EuroQol 5维度3水平效用评分0.65 vs 0.63,差值0.02(95%CI -0.00至0.04,P=0.10),无显著差异。
- 短期储存组随访期间再入院天数较长期储存组少3.0天(95%CI -5.3至-0.8,P=0.01),其余资源使用无显著差异。
- 调整后总成本增量-2358美元(95%CI -5586至711),增量质量调整生命年0.003(95%CI -0.003至0.008),均无显著差异。
- 作者结论:不考虑实施最新鲜可用红细胞策略的额外供应成本,该策略与标准输血实践相比未改善生活质量或减少其他成本。
适用人群与场景
- 成人患者,预期ICU停留至少24小时,且已决定输注至少1个单位红细胞。
- 研究场景为59个ICU、5个国家。
处置流程与药物剂量
- 患者随机接受最新鲜或最陈旧可用相容红细胞单位(标准实践),由医院输血服务提供。
研究设计与关键结果
- 研究类型:在完整年龄of blood临床试验(TRANSFUSE)基础上进行的首次经济学评价,评估红细胞储存时间对重症成人生活质量和成本的影响。
- 样本量:59个ICU、5个国家;人群为预期ICU停留至少24小时且已决定输注至少1个单位红细胞的成人。
- 干预与对照:随机接受最新鲜或最陈旧可用相容红细胞单位(标准实践)。
- 主要终点结果:6个月EuroQol 5维度3水平效用评分短期储存组0.65 vs 长期储存组0.63,差值0.02(95%CI -0.00至0.04,P=0.10),无显著差异。
- 关键次要终点:短期储存组随访期间再入院天数较长期储存组少3.0天(95%CI -5.3至-0.8,P=0.01);其余资源使用无显著差异。
- 成本与质量调整生命年:调整后总成本增量-2358美元(95%CI -5586至711),增量质量调整生命年0.003(95%CI -0.003至0.008),均无显著差异。
证据类型、等级与局限
- 证据类型:基于随机对照试验的经济学评价。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,不考虑实施最新鲜可用红细胞策略的额外供应成本,该策略与标准输血实践相比未改善生活质量或减少其他成本。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Trials comparing the effects of transfusing RBC units of different storage durations have considered mortality or morbidity as outcomes. We perform the first economic evaluation alongside a full age of blood clinical trial with a large population assessing the impact of RBC storage duration on quality-of-life and costs in critically ill adults.
DESIGN: Quality-of-life was measured at 6 months post randomization using the EuroQol 5-dimension 3-level instrument. The economic evaluation considers quality-adjusted life year and cost implications from randomization to 6 months. A generalized linear model was used to estimate incremental costs (2016 U.S. dollars) and quality-adjusted life years, respectively while adjusting for baseline characteristics.
SETTING: Fifty-nine ICUs in five countries.
PATIENTS: Adults with an anticipated ICU stay of at least 24 hours when the decision had been made to transfuse at least one RBC unit.
INTERVENTIONS: Patients were randomized to receive either the freshest or oldest available compatible RBC units (standard practice) in the hospital transfusion service.
MEASUREMENTS AND MAIN RESULTS: EuroQol 5-dimension 3-level utility scores were similar at 6 months-0.65 in the short-term and 0.63 in the long-term storage group (difference, 0.02; 95% CI, -0.00 to 0.04; p = 0.10). There were no significant differences in resource use between the two groups apart from 3.0 fewer hospital readmission days (95% CI, -5.3 to -0.8; p = 0.01) during follow-up in the short-term storage group. There were no significant differences in adjusted total costs or quality-adjusted life years between the short- and long-term storage groups (incremental costs, -$2,358; 95% CI, -$5,586 to $711) and incremental quality-adjusted life years: 0.003 quality-adjusted life years (95% CI, -0.003 to 0.008).
CONCLUSIONS: Without considering the additional supply cost of implementing a freshest available RBC strategy for critical care patients, there is no evidence to suggest that the policy improves quality-of-life or reduces other costs compared with standard transfusion practice.
参考来源
- Irving A, Higgins A, Ady B, et al. Fresh Red Cells for Transfusion in Critically Ill Adults: An Economic Evaluation of the Standard Issue Transfusion Versus Fresher Red-Cell Use in Intensive Care (TRANSFUSE) Clinical Trial. Crit Care Med. 2019. PMID: 31008734. doi:10.1097/CCM.0000000000003781
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。